TRUFFLE-CAPITAL
8.7.2021 08:02:05 CEST | Business Wire | Press release
Created by the private equity firm Truffle Capital and the research and consulting firm teknowlogy | CXP-PAC, the Truffle 100 2021 provides an overview of the French software industry by analyzing the activity of the top 100 companies in the sector during 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005107/en/
- This period was marked by several notable highlights: with a +6.6% increase, the growth in activity in the sector reached record highs, i.e. €11.6 billion; however, a record number of companies (33%) posted a fall in revenue.
- For the first time since 2013, the difference between the 50th and the 100th publishers decreased; but with 35% of the sector's revenue in 2020, the weighting of the company in first place continues to grow (+2 pts in 2020)
The Truffle 100 clearly shows that the anticipated market shock has not affected the whole software industry. Nevertheless, the companies have put forward a shared vision of the future of the market.
- The cloud is now considered by 92% of companies as the trend that will provide momentum in the sector over the coming years. This new trend, driven by the crisis, recorded a growth of +16 pts compared to the ranking published in 2020.
- In light of this situation, three-quarters of the companies plan to increase their workforce, and three-quarters also plan to ramp up their R&D projects.
Commenting on this 16th edition of Truffle 100, Cédric Ô, French Secretary of State for the Digital Economy, concluded: "In similar fashion to previous years, the development of the sector has been achieved by the long-standing efforts of its stakeholders and their capacity to anticipate the major technological breakthroughs which are, in the digital industry, more frequent and clearer to distinguish than in other industries ".
Bernard-Louis Roques, Managing Director and co-founder of Truffle Capital declared: "At a time when the ability to respond to events and the management of expertise proved vital, the French software industry played a civic role and created jobs on the domestic marke t".
Nadia Idrissi, Chairwoman of teknowlogy | CXP-PAC, added: "Highly topical themes such as the cloud, cybersecurity and the remote workplace have driven the market and allowed the majority of publishers, who are - on the whole - well prepared, to deliver revenue growth. [...] Companies using software solutions are picking up the pace of this forced march towards major digital transformation investments, and this also applies to industrial processes ".
The 16th edition of the Truffle 100 is available on the following website: https://www.truffle100.fr/
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (MedTech and Biotech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Truffle Capital manages €700 million in assets. Since its creation, it has raised nearly €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds, including €140 million in Fintech/Insurtech.
Further information: www.truffle.com — Twitter: @trufflecapital
About teknowlogy Group
teknowlogy | CXP-PAC teknowlogy | CXP-PAC is the leading European independent analysis and consulting firm in the field of software, IT services and digital transformation. As a privileged partner of European user companies, it offers them assistance in defining their digital strategy, managing projects and reducing the risks linked to technological choices and their implementation.
Owing to its knowledge of market trends and user-company expectations, teknowlogy | CXP-PAC helps software publishers and ESNs to better establish, execute and promote their own strategy in line with market expectations and in anticipation of future needs.
Capitalizing on more than 40 years of experience, teknowlogy | CXP-PAC has a network of 50 experts based in Paris, Munich, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom